Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > Cancer treatments do not impair COVID-19 survival

Cancer treatments do not impair COVID-19 survival

Journal
JAMA Network Open
    Reuters - 04/03/2022 - Powerful cancer therapies do not increase the risk of death for cancer patients with COVID-19, according to research based on data from the UK Coronavirus Cancer Monitoring Project.

    Researchers looked at 2,515 adults with COVID-19 who were receiving - or had recently received - systemic cancer treatments such as chemotherapy, immunotherapy, hormonal therapy, or certain targeted drugs. Half the patients in the study were older than 72.

    Within a week after COVID-19 diagnosis, 38% of the patients had died. Overall, patients with lung cancer or blood cancers were at higher risk for death. Chemotherapy, however, did not affect patients' risk of death from the virus, and immunotherapy actually improved the odds of survival, according to a report published in JAMA Network Open.

    Earlier studies of COVID-19 patients have found that those with cancer have poorer outcomes, but that may be due to "age, sex, comorbidities, and cancer subtype rather than anticancer treatments," the research team concluded.

    SOURCE: https://bit.ly/3MlMnHP JAMA Network Open, online February 21, 2022.

    By Reuters Staff



    Posted on